patients (66 with solid tumor, 36 with lymphoma, 14 with multiple myeloma, one with acute leukemia) underwent 178 cycles of high-dose chemotherapy and autologous stem cell transplantation (ASCT) at our institution. We retrospectively analyzed the infectious complications that occurred after ASCT. Median duration of neutropenia (granulocyte count Ͻ0.5 × 10 9 /l ) was 8 days, the overall incidence of fever requiring antimicrobial treatment was 63%. 35.4% of patients had fever of unknown orign (FUO), whereas primary bacteremia occurred in 21.3%, pneumonia in 3.4% and severe skin infection in 1.1% of patients. Invasive fungal infections occurred in three, and enterocolitis in one patient. Infection was fatal in three patients (2.6%), in each case due to septic shock. The most frequently isolated pathogens were Grampositive cocci. Median time to defervescence with antimicrobial therapy was 4 days (6 days in patients with bacteremia or other severe infection, and 3 days in patients with FUO). First-line antimicrobial therapy was successful in 65% of patients with FUO and 30.6% of patients with documented infections. With respect to the incidence, type and clinical course of infection, no significant differences between patients with lymphoma or multiple myeloma and those with solid tumors were detected. Bone Marrow Transplantation (2001) 27, 525-529.
with increasing frequency in Europe, 1 predominantly for breast cancer, malignant lymphoma, multiple myeloma, acute leukemia, ovarian cancer, testicular cancer and sarcoma. Despite the fact that numerous reports on safety, feasibility and efficacy of autologous SCT have been published, infectious complications after high-dose chemotherapy and SCT have only rarely been analyzed in detail. [2] [3] [4] [5] In contrast to patients with high-grade hematologic malignancies, patients with solid tumors are regarded as a low-risk group with regards to the likelihood of life-threatening, treatment-associated infections. 6 It is yet undetermined, whether there are significant differences in infectious complications between patients with hematologic malignancies and with solid tumors undergoing high-dose chemotherapy and autologous SCT.
In our study, we retrospectively analyzed the incidence, type and severity of infectious complications in 117 consecutive, unselected patients undergoing high-dose chemotherapy and autologous SCT at our institution.
Patients and methods
Between November 1994 and May 1998, 117 patients underwent 178 cycles of high-dose chemotherapy and SCT. All episodes of fever and/or documented infections during neutropenia (defined as an absolute polymorphonuclear leukocyte count Ͻ0.5 × 10 9 /l) were included. Clinical characteristics are summarized in Table 1 .
All patients except those with sarcoma (n = 26) received oral antimicrobial prophylaxis consisting of ciprofloxacin (500 mg twice daily p.o.) and fluconazole (200 mg twice daily p.o.) or trimethoprim-sulfamethoxazole (800 + 160 mg every 8 h p.o.) and amphotericin B suspension (400 mg every 4 h p.o.). Until September 1996, all patients additionally received antiviral prophylaxis with acyclovir (400 mg twice daily p.o. or 5 mg/kg i.v. per day) until day +100 after SCT. All patients not given antimicrobial prophylaxis received repetitive myelosuppresive chemotherapy for sarcoma (ifosfamide 2.5 g/m 2 , days 1-5 and epirubicine 45 mg/m 2 days 2, 3), whereas all patients given antimicrobial prophylaxis underwent myeloablative high-dose chemotherapy. All patients were treated in single rooms on a sep- arate ward with intensified hospital hygiene regulations including a special low-germ diet.
All episodes of fever from starting high-dose-chemotherapy to discharge were documented.
According to the recommendations and guidelines of the Infectious Disease Society of America (IDSA), 6 diagnostic procedures in event of first fever, defined as Ͼ38.3°C or at least twice Ͼ38.0°C/within 12 h, included a repeat physical examination, chest radiography and blood cultures from peripheral veins and from the venous catheter. Further investigations were done if indicated. The diagnosis of a documented infection was based on positive blood cultures and/or appropriate clinical findings. Diagnosis of a catheterrelated infection was based on clinical signs such as an inflamed or draining catheter entry site or a positive culture from the central venous line, if this was removed. Definition of response to treatment and defervescence time were: body temperature below 37.5°C and clinical improvement for more than 24 h.
First-line interventional antimicrobial therapy consisted of a broad-spectrum ␤-lactam antibiotic with or without an aminoglycoside or, in case of impaired renal function, a double ␤-lactam combination. In patients with evidence of central venous catheter and/or skin infection, a glycopeptide antibiotic was added empirically.
All data were analyzed with descriptive statistical methods. Statistical significance or difference betweeen diagnostic groups was calculated using 2 test or log rank test.
Results
A median number of 3.27 × 10 6 autologous CD34-positive cells per kg body weight was transplanted. Median duration of neutropenia was 8 days (range, 4 to 28 days) (see Table 2 ).
One hundred and twelve of 178 cycles (63%) of highdose chemotherapy and ASCT were complicated by fever requiring antimicrobial intervention. Fever of unknown origin accounted for 56.3%, and bacteremia for another 33.9% of febrile episodes. Coagulase-negative staphylococci (CNS) were most frequently isolated in patients with bacteremia. Table 3 shows the association between bacteremia with CNS and infections at the catheter insertion site. Gram-negative bacteremia occurred in 6.3% of episodes only.
Three patients had invasive fungal infections: two pneumonias from Aspergillus fumigatus and one fungemia caused by Candida glabrata. All were successfully treated with parenteral amphotericin B. No severe viral infections were observed. Lung infiltrates emerged in six patients and were associated with a longer time to response to antimicrobial treatment (median 12 days) as compared with other subtypes of documented infection. Three patients died from septic shock, all caused by streptococcal bacteremia. Details of clinically and microbiologically documented infections are given in Table 4 .
Analyzing the incidence, epidemiology and clinical course of infectious complications, no statistically significant differences between patients with hematologic malignancies or solid tumors could be detected (Table 2) . We divided the patients with hematologic malignancies in subgroups according to the underlying disease and again, no significant differences could be detected (Table 2) .
Median time of response to antimicrobial treatment was 4 days (range, 1 to 23 days). Patients with FUO defervesced after a median time of 3 days. If a clinically documented infection or bacteremia was present, median time to defervescence was 6 days (Table 5) .
We observed a markedly better response to first-line antibiotic therapy in FUO patients compared to patients with documented infections. All patient with FUO responded to a first-or second-line antimicrobial chemotherapy, whereas in 22.9% of patients with documented infections, a thirdor fourth-line antimicrobial chemotherapy was required ( Table 6) .
Comparison of patients who had been given selective oral antimicrobial prophylaxis with those who had received no prophylaxis showed no significant differences with respect to incidence of acquired infections, ie FUO and/or documented infections (Table 7) .
Discussion
The 63% incidence of febrile complications observed in our patients after high-dose chemotherapy and autologous SCT corresponds well to reports from other study groups. 7, 8 However, they are in contrast to many investigators who have reported up to 100% incidence of febrile neutropenia in this patient population, 3,9-14 and Mossad et al 2 and Shea et al 15 who reported a lower incidence. This might be due to different criteria for patient selection and indications to start antimicrobial therapy. Unfortunately, these criteria are not specified in the majority of reports cited. A significant impact of antimicrobial prophylaxis, is not evident, however, since a very high incidence of febrile complications is reported by some centers, regardless of broad-spectrum antimicrobial prophylaxis. 7, 9 The severity of infectious complications in our study was in general moderate. As did other investigators, we observed a predominance of Gram-positive bacteremia among documented infections 2, 3, 7, 16 and identified indwelling central venous catheters as the main risk factor for this type of infection. With respect to these observations it appears useful to strengthen efforts to reduce catheterrelated infections in patients undergoing high-dose chemotherapy. Taking into account the increasing emergence of resistance to glycopeptides among Gram-positive organisms, routine antibiotic prophylaxis with i.v. vancomycin cannot be recommended. Moreover, Rackoff et al 17 found no benefical effect of vancomycin plus heparin on the risk of bacteremia in a randomized trial of children undergoing chemotherapy or parenteral nutrition after surgical intervention. Use of central-venous catheters coated with minocycline and rifampicin has been shown to reduce catheterrelated infections 18 and might be useful in high-risk patients. However, their use has not been documented in randomised studies, presumably because of their high cost. Beyond this, the insertion procedure has been identified as being one of the main risk factors for a subsequent catheterrelated infection. The use of maximum sterile barriers may help to decrease the rate of infectious complications associated with central-venous catheters.
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Invasive fungal infections are remarkably infrequent in patients undergoing high-dose chemotherapy and autologous SCT. Antifungal prophylaxis has not been shown to be useful for patients with short periods of neutropenia after PBSCT. Gilbert et al 8 reported a fungemia rate of about 4%, and no patient affected had received antifungal prophylaxis. In our own study, only one patient not taking antifungal prophylaxis developed a fungemia caused by Candida glabrata, a fungal pathogen known to be potentially resistant to azole antifungals. The usefulness of routine antifungal prophylaxis with one of the commercially available azoles, ie fluconazol and itraconazole, therefore remains to be determined in the patient population addressed here.
The majority of infectious episodes in our study were associated with a fever of unknown origin and responded well to standard antimicrobial therapy. Median time to defervescence was only 3 days in this group of patients. In contrast, patients with documented infections had a higher risk of a more complicated clinical course.
The infection-related mortality in our as well as other studies is very low. Weaver et al 20 observed a mortality rate of 1.5% directly attributable to infections in a group of 1000 patients undergoing high-dose chemotherapy and autologous SCT. Therefore, it appears appropriate to regard patients after autologous stem cell support as a low-risk group with respect to life-threatening infections. In a recent Table 7 Comparison of infectious complications in patients with vs without oral antimicrobial prophylaxis report by the International Antimicrobial Therapy Cooperative Group of EORTC, patients undergoing HDT and ASCT were also included in a study on oral vs parenteral antibiotics for treatment of fever and infections in patients with expected short-term neutropenia (ie granulocyte count Ͻ500/l for р10 days). The success rate was 86% in patients receiving ciprofloxacin plus amoxicillin-clavulanate and 84% in patients receiving ceftriaxone plus amikacin. 21 These data indicate that a significant proportion of patients with febrile episodes after high-dose chemotherapy and autologous SCT might be managed on an out-patient basis.
Confirming other study reports 2,3 we detected no significant differences between patients with multiple myeloma or lymphoma and those with solid tumors with respect to infectious complications following high-dose chemotherapy and autologous SCT. This appears remarkable because most patients with hematologic malignancies had received multiple cycles of intensive chemotherapy prior to autologous SCT. On the other hand, most studies on high-dose chemotherapy report a median duration of severe neutropenia of less than 10 days. According to the clinical data of Bodey et al, 22 duration of neutropenia seems to be the main risk factor for severe infections independent of the underlying disease.
In conclusion, the majority of patients undergoing highdose chemotherapy and autologous SCT can be regarded as low-risk with respect to infectious complications during neutropenia. Further studies are required to identify valid prognostic factors, to clarify the role of oral antimicrobial prophylaxis, and to reduce the incidence of venous catheterrelated infections in these patients.
